Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -18.06M | -9.92M | -10.78M | -6.16M | -15.80M |
| Total Depreciation and Amortization | 14.60K | 56.20K | 62.20K | 34.20K | 29.20K |
| Total Amortization of Deferred Charges | 5.80K | 5.80K | 5.80K | -- | -- |
| Total Other Non-Cash Items | 6.29M | -4.25M | -4.10M | -8.95M | 1.20M |
| Change in Net Operating Assets | 2.53M | 1.62M | 833.70K | 1.80M | 2.19M |
| Cash from Operations | -9.22M | -12.49M | -13.97M | -13.28M | -12.38M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 88.20K | 88.20K | 88.20K | 88.20K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -500.00K | -500.00K | -500.00K | -500.00K |
| Cash from Investing | 88.20K | -411.80K | -411.80K | -411.80K | -500.00K |
| Total Debt Issued | 31.80K | 31.80K | 31.80K | -- | -- |
| Total Debt Repaid | -644.60K | -644.60K | -620.50K | -606.40K | -603.50K |
| Issuance of Common Stock | 6.23M | 10.58M | 14.40M | 15.66M | 15.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.58M | 9.97M | 13.81M | 15.06M | 15.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.55M | -2.93M | -573.60K | 1.37M | 2.35M |